Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: Effect on clonogenicity in both two-and three-dimensional models

Cancer Gene Therapy

Volumn 7, Issue 12, 2000, Pages 1529-1536

  Carlin, S ^a   Cunningham, S H ^a   Boyd, M ^a   McCluskey, A G ^a   Mairs, R J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Clonogenicity; NIS; Radiological bystander effect; Radiotherapy; Tumor cells

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; SODIUM IODIDE;

ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SPHEROID CELL;

EID: 0034492181     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700264     Document Type: Article

References (34)

1. How safe for the patient is iodine-131 therapy for differentiated thyroid carcinoma?
2. Polarisation of thyroid cell culture: Evidence for the basolateral localisation of the iodine pump and of the thyroid-stimulating hormone receptor-adenyl cyclase complex
3. Cloning of the human iodide symporter
4. - symporter (NIS): Recent advances
5. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene
6. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines
7. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of it's complimentary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa
8. Cloning and characterisation of the thyroid iodide transporter
9. - symporters
10. The determination of enzyme dissociation constants
11. The mechanism of action of thiourylene antithyroid drugs
12. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions
13. 131IIUDR to human glioma cells in monolayer of spheroid culture: Effect of proliferative heterogeneity and radiation crossfire
14. 131I-meta-iodobenzylguanidine
15. Effects of intercellular contact on repair of radiation damage
16. Drug and radiation resistance in spheroids: Cell contact and kinetics
17. Increased radioresistance of cells in cultured multicell spheroids: I. Dependence on cellular interaction
18. Radiation response of connexin43-transfected cells in relation to the contact effect
19. 131I-labeled monoclonal antibody in ovarian cancer multicell spheroids
20. Multicellular tumor spheroids in radiation biology
21. Dosimetric aspects of radiolabeled antibodies for tumor therapy
22. Microdosimetric considerations in the targeted radiotherapy of cancer
23. 125I ] iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes
24. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells
25. Approaches to enhance cancer radiotherapy employing gene transfer methods
26. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene
27. Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector
28. 2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer
29. - symporter. Mechanism, stoichiometry, and specificity
30. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govem clinical choice of appropriate regimes
31. 211At]astatide accumulation in normal tissues: Preliminary evaluation of seven potential compounds
32. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro
33. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite